30 Day Trial

ConforMIS, Orthofix and OrthoPediatrics Report Preliminary 4Q18 and FY 2018 Results

Share:

Preliminary results for ConforMIS, Orthofix and OrthoPediatrics were mixed. While ConforMIS’ net revenue for the year grew in the double digits, adjusting for product-only revenue reveals a mostly flat year. Orthofix rode strong spinal implant sales to mid-single-digit growth for the year but was impacted by the slowdown in the biologics market. OrthoPediatrics continued to leverage its leadership position in the pediatric space to achieve aggressive sales growth for both the quarter and year.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.